title: Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. I. Biochemical results.
abstract: An established anterior cruciate ligament deficiency-induced articular cartilage degeneration was used to evaluate the effects of intrasynovial injection of hyaluronic acid upon cartilage destruction. In this study, proteoglycan solubility under associative and dissociative conditions was compared in two treatment protocols at intervals of seven, 13, and 17 weeks after surgical breakage of the anterior cruciate ligament in 2.5-year-old Beagle dogs. Untreated joints showed a marked increase in both total soluble glycosaminoglycan (GAG measured as uronic acid) and in the associative fraction. In both treated groups, there was a reduced amount of soluble GAG. Cessation of treatment after seven weeks caused gradual regression, with an increasing amount of CaCl2-soluble material in the associative fraction, while inception at seven weeks gave biochemical evidence of reversal, with increasing GAG present in the guanidine-soluble (dissociative) fraction on the insoluble residue. The protective effects of hyaluronic acid suggest the potential clinical application of this therapy in retarding the advance of osteoarthritis.
authors.affiliation: University of Padua, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Abatangelo
authors.forename: P
authors.initials: P
authors.lastname: Botti
authors.forename: M
authors.initials: M
authors.lastname: Del Bue
authors.forename: G
authors.initials: G
authors.lastname: Gei
authors.forename: J C
authors.initials: JC
authors.lastname: Samson
authors.forename: R
authors.initials: R
authors.lastname: Cortivo
authors.forename: A
authors.initials: A
authors.lastname: De Galateo
authors.forename: M
authors.initials: M
authors.lastname: Martelli
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D006025:Glycosaminoglycans / Q000378:metabolism; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D007270:Injections, Intra-Articular; D007719:Knee Joint / Q000378:metabolism; D008592:Menisci, Tibial / Q000473:pathology; D010003:Osteoarthritis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011509:Proteoglycans / Q000378:metabolism*; D013583:Synovial Membrane / Q000473:pathology; D014574:Uronic Acids / Q000378:metabolism
chemical_list: D006025:Glycosaminoglycans; D011509:Proteoglycans; D014574:Uronic Acids; D006820:Hyaluronic Acid